Real‐world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trials
Journal of Pediatric Gastroenterology and Nutrition · 2024-03 · 78 (3) · 506-513
DOI: 10.1002/jpn3.12101 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 09.02.2024. Verfasst von Ryan Himes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Ochsner Health Center for Children, New Orleans, Louisiana, USA. Hauptthemen laut MEDLINE: Alagille Syndrome, Benzothiepins, Cholestasis. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mirum Pharmaceuticals, Inc..
Abstract (Originalsprache)
Objective
Maralixibat, an ileal bile acid transporter inhibitor, is the first drug approved by the U.S. Food and Drug Administration for the treatment of cholestatic pruritus in patients aged ≥3 months with Alagille syndrome (ALGS). Approval was based on reductions in pruritus from the pivotal ICONIC trial, information from two additional trials (ITCH and IMAGO), and long‐term extension studies. Although participants in these trials met strict inclusion and exclusion criteria, patients have received maralixibat under broader circumstances as part of an expanded access program or commercially. The expanded access and postapproval settings inform a real‐world understanding of effectiveness and safety. The objective was to report on the use of maralixibat in the real‐world setting in eight patients who otherwise would not have met entrance criteria for the clinical trials, providing unique insights into its effectiveness in the management of ALGS.
Methods
We reviewed records of patients with ALGS who received maralixibat but would have been excluded from trials due to surgical biliary diversion, reduction of antipruritic/cholestatic concomitant medications, administration of medication through a gastrostomy or nasogastric tube, or use in patients under consideration for transplantation.
Results
Maralixibat appeared to be effective with reductions in pruritus compared to baseline. Consistent with clinical trials, maralixibat was well tolerated without appreciable gastrointestinal complications. Liver enzyme elevations were observed but were interpreted as consistent with normal fluctuations observed in ALGS, with no increases in bilirubin.
Conclusion
Maralixibat may be effective and well tolerated in patients with ALGS in broader clinical contexts than previously reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Gastroenterology, Hepatology, and Nutrition, Ochsner Health Center for Children, New Orleans, Louisiana, USA.
- Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco, California, USA.
- Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Johns Hopkins Children's Center, Baltimore, Maryland, USA.
- Department of Pediatric Gastroenterology, University of California Los Angeles, Los Angeles, California, USA.
- Pediatric Gastroenterology, Hepatology, and Liver Transplant, AdventHealth for Children and AdventHealth Transplant Institute, Orlando, Florida, USA.
ORCID-Profile: Ryan Himes
Förderung
- Mirum Pharmaceuticals, Inc.
Zitieren
APA
Himes, R., Rosenthal, P., Dilwali, N., Smith, K., Venick, R., & Gonzalez-Peralta, R. P. (2024). Real‐world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trials. Journal of Pediatric Gastroenterology and Nutrition, 78(3), 506-513. https://doi.org/10.1002/jpn3.12101
Vancouver
Himes R, Rosenthal P, Dilwali N, Smith K, Venick R, Gonzalez-Peralta RP. Real‐world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trials. Journal of Pediatric Gastroenterology and Nutrition. 2024;78(3):506-513. doi:10.1002/jpn3.12101
BibTeX
@article{Himes2024,
author = {Himes, Ryan and Rosenthal, Philip and Dilwali, Natasha and Smith, Kathryn and Venick, Robert and Gonzalez-Peralta, Regino P},
title = {Real‐world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trials},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
volume = {78},
number = {3},
pages = {506--513},
doi = {10.1002/jpn3.12101}
}
EUVIMED